ONCOS-102 is under clinical development by Circio Holding and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ONCOS-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONCOS-102 overview
ONCOS-102 is under development for the treatment of solid tumors including malignant pleural mesothelioma, peritoneal cancer, epithelial ovarian cancer and metastatic colorectal cancer. It is administered through intratumoral and intraperitoneal injection. ONCOS-102 is a genetically modified oncolytic adenovirus (AdV5) carrying a genetic cassette for mRNA-based expression of the cytokine granulocyte macrophage colony stimulating factor (GM-CSF) and is being developed based on virus-based immunotherapy platform.
See Also:
It was also under development for soft tissue sarcoma, refractory advanced melanoma and metastatic castration-resistant prostate cancer (second and third line therapy).
Circio Holding overview
Circio Holding(Circio), formerly Targovax, is a developer and commercialize of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02 and ONCOS-200 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer cells, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company has operations in Norway and Finland. Circio is headquartered in Oslo, Norway.
For a complete picture of ONCOS-102’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.